L-Asparaginase as the gold standard in the treatment of acute lymphoblastic leukemia: a comprehensive review

María Tosta Pérez, Lisandra Herrera Belén, Pablo Letelier, Yolanda Calle, Adalberto Pessoa, Jorge G Farías

Research output: Contribution to journalArticlepeer-review


L-Asparaginase is an antileukemic drug long approved for clinical use to treat childhood acute lymphoblastic leukemia, the most common cancer in this population worldwide. However, the efficacy and its use as a drug have been subject to debate due to the variety of adverse effects that patients treated with it present, as well as the prompt elimination in plasma, the need for multiple administrations, and high rates of allergic reactions. For this reason, the search for new, less immunogenic variants has long been the subject of study. This review presents the main aspects of the L-asparaginase enzyme from a structural, pharmacological, and clinical point of view, from the perspective of its use in chemotherapy protocols in conjunction with other drugs in the different treatment phases. [Abstract copyright: © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.]
Original languageEnglish
Pages (from-to)150
JournalMedical oncology (Northwood, London, England)
Issue number5
Early online date15 Apr 2023
Publication statusE-pub ahead of print - 15 Apr 2023


  • Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
  • Asparaginase - therapeutic use - adverse effects
  • Drug-Related Side Effects and Adverse Reactions
  • Immunogenicity
  • Acute lymphoblastic leukemia
  • Hypersensitivity
  • Asparaginase
  • Drug Hypersensitivity
  • Humans
  • Child
  • Antineoplastic Agents - adverse effects
  • Antineoplastic agent

Cite this